Search

Association Between Housing Instability and Severity of Psoriasis and Psoriatic Arthritis: A Cross-Sectional Study

Page 321-327

Clinical Manifestations and Management Considerations of Psoriasis Affecting The Nail Unit

Page 12-29

Psoriasis Therapies and the Risk of Cutaneous Malignancy

Page 55-63

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Page 112-118

Linear Psoriasis: A Case Report of a 71-Year-Old Female

Page 80-84

Psoriasis in Pregnancy: A Review

Page 119-123

Transitioning Between Biologics

Page 374-380

Expert Panel Discussion among Psoriasis and Psychodermatology Specialists: How Best to Manage Depressed Psoriasis Patients with Brodalumab

Page 368-373

Caffeine in the Treatment of Atopic Dermatitis and Psoriasis: A Review

Page 59-71

Biologic Prescribing Patterns Among Mount Sinai Psoriasis Patients: Results of a Retrospective Chart Review

Page 106-111

Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis

Page s10

Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Page s24

Reporting of Quality of Life in Clinical Trials of Biologics for Plaque Psoriasis: A Systematic Review

Psoriasis with End Stage Renal Disease Successfully Treated with Ustekinumab: A Case Report

Page 342-344

Safe use of Interleukin-17 Inhibitors for Psoriasis and Psoriatic Arthritis in Two Patients with a History of Lymphoproliferative Disease

Page 256-259

Successful Treatment of Generalized Pustular Psoriasis of Pregnancy with Oral Cyclosporine

Page 252-255

Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Page s97

The Impact of Psoriasis on the Quality of Life of Patients in San Antonio, TX

Page 331-334

Defining and Treating Moderate Plaque Psoriasis in a Real-World Clinical Setting: A Dermatologist Survey and Prospective 6-Month Chart Review of Patients Treated with Apremilast

Page s7

Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Page s23

A Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Clobetasol Propionate Cream (Impoyz™), 0.025% versus Clobetasol Propionate (Temovate®)

Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab

Page s5

Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs

Page 72-81

A Review of Biologics and Other Treatment Modalities in HIV-Associated Psoriasis

Rapid Efficacy of Ixekizumab for Pediatric Acute Generalized Pustular Psoriasis

Page 667-671